MBX Biosciences, Inc. cotiza a 52.80 USD y tiene una capitalización bursátil de $2.5B. Datos fundamentales de la SEC EDGAR con hasta 20 años de histórico, insiders, institucionales y valoración DCF.Más empresas del sector Salud
MBX Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of precision peptide therapies for the treatment of endocrine and metabolic disorders. Its lead product candidate is Canvuparatide (MBX 2109), a parathyroid hormone peptide prodrug, which is in Phase 3 clinical t…
| Periodo | 2026-11 | 2026-08 | 2026-05 | 2026-03 |
|---|---|---|---|---|
| Real | — | $-0.78 | $-0.51 | $-0.49 |
| Estimado | $-0.84 | $-0.59 | $-0.58 | $-0.60 |
| Sorpresa | — | -32.2% | +12.1% | +18.3% |
| Métrica | MBX | Mediana Sector | Δ |
|---|---|---|---|
| Gross Margin | — | 57.0% | — |
| Operating Margin | — | -38.6% | — |
| Net Margin | — | -33.6% | — |
| FCF Margin | — | -13.9% | — |
| ROE | -23.6% | -40.4% | +16.8% |
| ROA | -22.6% | -32.0% | +9.4% |
| Current Ratio | 24.62 | 2.84 | +21.78 |
| Debt / Equity | — | 0.28 | — |